Michael M. Abecassis - 10 Aug 2021 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Michael M. Abecassis
Issuer symbol
PMCB
Transactions as of
10 Aug 2021
Net transactions value
$0
Form type
3
Filing time
20 Aug 2021, 20:35:44 UTC
Next filing
22 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMCB Common Stock 1,667 10 Aug 2021 Direct F1
holding PMCB Common Stock 800 10 Aug 2021 By Transplant Consulting LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 334 $87.00 Direct F1, F2
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 800 $87.00 By Transplant Consulting LLC F1, F2
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 334 $102.45 Direct F1, F2
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 334 $55.50 Direct F1, F2
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 334 $37.05 Direct F1, F2
holding PMCB Stock Option (right to buy) 10 Aug 2021 Common Stock 334 $16.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
F2 The exercise price has been adjusted to reflect the Reverse Split.